Market Cap 556.80M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 115.88
Profit Margin -43.33%
Debt to Equity Ratio 1.61
Volume 9,158,899
Avg Vol 3,826,596
Day's Range N/A - N/A
Shares Out 265.15M
Stochastic %K 3%
Beta 0.68
Analysts Strong Sell
Price Target $6.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
GR1ZZLYBEARZ
GR1ZZLYBEARZ Oct. 31 at 7:56 AM
$AKBA $AKBA there’s too much lining up for this not to be a push down before a rip. So many potential catalysts in the next 1-6 months. Short volume decreased from the 60-70% area tues/wed to 48% yesterday… short days to cover went from 16 a few days ago down to 3 yesterday.
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 7:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AKBA Current Share Price: $2.10 Contracts: $AKBA January 15, 2027 $2 Calls Scale in: $0.80- $0.98 Scale out: $1.24-$1.60 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
SPECTRAL1
SPECTRAL1 Oct. 31 at 7:07 AM
0 · Reply
BioLove
BioLove Oct. 31 at 7:04 AM
$AKBA would like to see the price hold the low $2 s line until earnings...this is a very volatile sector/stock, and that would be a good sign. Of course, earnings will tell the story
0 · Reply
Azazel22
Azazel22 Oct. 31 at 5:44 AM
$AKBA this stock is a dud and i feel like i wasted to much time and money on it unfortunately
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 31 at 4:34 AM
Enter: $AKBA Calls Strike Price: $2 Expiry Date: NOV 21 2025 Buy in Price: $0.15 - $0.15 Sell Price: $0.31 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
piratepotatoman
piratepotatoman Oct. 31 at 3:31 AM
$AKBA 1.25 key entry
1 · Reply
Value_Runner
Value_Runner Oct. 31 at 2:56 AM
$AKBA kid accounts at fidelity can’t buy stocks below $5. Come on butler, get this thing moving! My kids want to buy some shares!!! Get us out of “penny stock” land! https://www.fidelity.com/go/youth-account/overview
0 · Reply
rvc617423
rvc617423 Oct. 31 at 2:50 AM
$AKBA hear this absurd and totally irrational thought - lmao, alright imagine if this was purposely dropped to $2 so that butler goes and offers a buyback of 25 million shares @ the offering price 🤔🤨🧐 and on that note, time for bed 😆
1 · Reply
cashupfront
cashupfront Oct. 31 at 2:31 AM
$AKBA somebody needs to ban this guy for Over hyping this shit Tired of your posts Mr.pithetic
1 · Reply
Latest News on AKBA
Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 10:21 AM EDT - 8 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript


Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 13, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates


Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics


GR1ZZLYBEARZ
GR1ZZLYBEARZ Oct. 31 at 7:56 AM
$AKBA $AKBA there’s too much lining up for this not to be a push down before a rip. So many potential catalysts in the next 1-6 months. Short volume decreased from the 60-70% area tues/wed to 48% yesterday… short days to cover went from 16 a few days ago down to 3 yesterday.
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 31 at 7:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AKBA Current Share Price: $2.10 Contracts: $AKBA January 15, 2027 $2 Calls Scale in: $0.80- $0.98 Scale out: $1.24-$1.60 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com
0 · Reply
SPECTRAL1
SPECTRAL1 Oct. 31 at 7:07 AM
0 · Reply
BioLove
BioLove Oct. 31 at 7:04 AM
$AKBA would like to see the price hold the low $2 s line until earnings...this is a very volatile sector/stock, and that would be a good sign. Of course, earnings will tell the story
0 · Reply
Azazel22
Azazel22 Oct. 31 at 5:44 AM
$AKBA this stock is a dud and i feel like i wasted to much time and money on it unfortunately
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 31 at 4:34 AM
Enter: $AKBA Calls Strike Price: $2 Expiry Date: NOV 21 2025 Buy in Price: $0.15 - $0.15 Sell Price: $0.31 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
piratepotatoman
piratepotatoman Oct. 31 at 3:31 AM
$AKBA 1.25 key entry
1 · Reply
Value_Runner
Value_Runner Oct. 31 at 2:56 AM
$AKBA kid accounts at fidelity can’t buy stocks below $5. Come on butler, get this thing moving! My kids want to buy some shares!!! Get us out of “penny stock” land! https://www.fidelity.com/go/youth-account/overview
0 · Reply
rvc617423
rvc617423 Oct. 31 at 2:50 AM
$AKBA hear this absurd and totally irrational thought - lmao, alright imagine if this was purposely dropped to $2 so that butler goes and offers a buyback of 25 million shares @ the offering price 🤔🤨🧐 and on that note, time for bed 😆
1 · Reply
cashupfront
cashupfront Oct. 31 at 2:31 AM
$AKBA somebody needs to ban this guy for Over hyping this shit Tired of your posts Mr.pithetic
1 · Reply
Holy_boy
Holy_boy Oct. 31 at 2:31 AM
$AKBA I predict the following scenario with the next gen HIF-PHI such as AB9030. Akebia will conduct phase 2/3 study on AB9030 on ARDS indication. If study result good, move AB9030 to phase 3 NDD CKD indication down the road. Phase 3 study on ARDS is much cheaper to carry out than CKD indication. The advantage of this pathway (compared to pursue Vada phase 3 NDD CKD study which is now cancelled) is longer patent protection, and getting ARDS indication/rev along the way, and higher chance of success with the most expensive study on NDD CKD indication. I see this pattern emerging in $ARDX latest ER where they talked about their next gen molecule in the pipeline. It is becoming easier for biopharma to modify their working molecules to improve its efficacy and safety profile, by harnessing new research tech like AI.
4 · Reply
Mr_Pithy
Mr_Pithy Oct. 31 at 1:36 AM
$AKBA TODAY MARKS EIGHT MONTHS FROM JUNE 30, 2026. “I always said AKBA is a $30 stock just based on the Vafseo dialysis dependent indication.” (10-28-25); “Only price target now is $30 by June 2026.” (08-10-25); “So a $30 June 30, 2026 target price given my revenue model is totally fine and is in the lower end of the fair value range.”($24-$67) (08-08-25, 09:23 p.m.); “$30 mark by June 30, 2026 is my only prediction.” (08-08-25, 10:01 a.m.); “EOY $30 stock price gets extended out to June 30, 2026.” (08-08-25, 9:54 a.m.); Thank you @hsainu. Good luck 🍀
3 · Reply
BULLZ820
BULLZ820 Oct. 31 at 12:34 AM
$AKBA hate to say it but unless the earnings is absolutely crazy good, even if it beats and is impressive but not like 200m, it will continue to be this way. Maybe down into 1s which is crazy for probably 300m+ in sales this year
8 · Reply
Justinkorr
Justinkorr Oct. 31 at 12:24 AM
$AKBA The day after a 32% crash, the stock couldn’t even rebound by 0.1%. At this point, I think the company’s only real hope is a buyout, and I just hope V is an appealing enough drug for potential buyers. Honestly, if someone offered me $3.5 to $4 per share, I’d sell without hesitation.
2 · Reply
piratepotatoman
piratepotatoman Oct. 31 at 12:18 AM
$AKBA thinking about reentering but only around 1.25-1.5
3 · Reply
sundancehold
sundancehold Oct. 30 at 11:59 PM
$AKBA We've been 100% controlled by some short outfit for at least 8 months. I assume they're dark pooling shares over to tutes. Anyone that has any doubts, check the daily evidence in the level 2 bid/ask stack at 3:57-3:59 PM EST. every single day. Most scoff at Mo, but I'm 98% certain his crew is the outfit.
1 · Reply
viber7
viber7 Oct. 30 at 11:54 PM
$AKBA 20% of patients had GI side effects on V. So 250K patients = 60% of 0.8 X 550K TAM. When do you think we get that high number? Probably 2027-8. So your PPS target of 8 is valid 2-3 years from now for DD alone. Any earlier would require Davita and Fresenius to be completely committed to V by next summer 2026. Davita, OK. Fresenius not sure.
1 · Reply
thenewguy77
thenewguy77 Oct. 30 at 11:52 PM
$AKBA So the math ain’t matching friends! As of yesterday and today the market cap is at around $550MM. Let’s assume for argument that for some reason V had zero growth and this quarter and aux holds its own as it has the past few quarters. That would mean V would be valued at 60MM (15mm per quarter) and aux would be valued at 200MM (50MM per quarter). Then we add the appropriate cash and cash equivalents at 140MM. The total value of the company would be at around 400MM. So somehow the market is value this company at nearly zero growth. I think once earnings come out, that will cause the reset we need to get us away from $2 a share. My estimates based on pure sales and a conservative multiple of 4x since this is a growth stock is 1.2BB. That’s 100MM of V, 200MM of aux and 140MM in cash.
2 · Reply
DonnyDonowitz
DonnyDonowitz Oct. 30 at 11:36 PM
$AKBA old legend here MaxbeakWettage's wife once said "WTF are you doing investing this much money in a CKD drug company!"
0 · Reply
Masonic11
Masonic11 Oct. 30 at 11:27 PM
$AKBA the grinch is a bitch.
1 · Reply
DollaDollaPils
DollaDollaPils Oct. 30 at 11:19 PM
0 · Reply
Soheil444
Soheil444 Oct. 30 at 11:18 PM
$AKBA problem is no matter how good earnings is price will still drop. so regardless if bad er we drop if good er we drop . thats what sucks about this stock
1 · Reply